Drug Profile
Metoprolol - IntelGenx
Alternative Names: INT-0001; INT-0001/2004Latest Information Update: 06 Oct 2021
Price :
$50
*
At a glance
- Originator IntelGenx Corp.
- Class Antihypertensives; Antimigraines; Class II antiarrhythmics; Heart failure therapies; Ischaemic heart disorder therapies; Propanolamines
- Mechanism of Action Beta 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hypertension
Highest Development Phases
- Discontinued Heart failure; Hypertension
Most Recent Events
- 08 Sep 2021 Discontinued - Phase-II for Heart failure in Canada (PO) (IntelGenx pipeline, September 2021)
- 08 Sep 2021 Discontinued - Phase-II for Hypertension in Canada (PO) (IntelGenx pipeline, September 2021)
- 30 Mar 2016 Suspended - Phase-II for Heart failure in Canada (PO)